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Abstract
 
Cross-linked fibrin is deposited in tissues surrounding wounds, inflammatory sites, or tumors
and serves not only as a supporting substratum for trafficking cells, but also as a structural barrier
to invasion. While the plasminogen activator-plasminogen axis provides cells with a powerful
fibrinolytic system, plasminogen-deleted animals use alternate proteolytic processes that allow
fibrin invasion to proceed normally. Using fibroblasts recovered from wild-type or gene-
deleted mice, invasion of three-dimensional fibrin gels proceeded in a matrix metalloproteinase
(MMP)-dependent fashion. Consistent with earlier studies supporting a singular role for the
membrane-anchored MMP, MT1-MMP, in fibrin-invasive events, fibroblasts from MT1-MMP–
null mice displayed an early defect in invasion. However, MT1-MMP–deleted fibroblasts cir-
cumvented this early deficiency and exhibited compensatory fibrin-invasive activity. The
MT1-MMP–independent process was sensitive to MMP inhibitors that target membrane-
anchored MMPs, and further studies identified MT2-MMP and MT3-MMP, but not MT4-
MMP, as alternate pro-invasive factors. Given the widespread distribution of MT1-, 2-, and
3-MMP in normal and neoplastic cells, these data identify a subset of membrane-anchored
MMPs that operate in an autonomous fashion to drive fibrin-invasive activity.
Key words: matrix metalloproteinases • MT-MMP • ﬁbrin • proteolysis • invasion
 
Introduction
 
In response to tissue damage, inflammation, or neoplastic
growth, a provisional matrix largely composed of cross-
linked fibrin and fibronectin is deposited at the affected site
(1, 2). While the fibrin scaffolding functions initially as a
structural support for infiltrating fibroblasts, endothelial
cells, leukocytes, or tumor cells, the cross-linked network
also acts as a physical barrier to cell traffic (2–14). Currently,
invading cells are thought to use proteinases to access the fi-
brin matrix with proteolysis purposefully restricted to the
pericellular milieu of the ingressing cells (3, 14, 15). In this
manner, the overall structural integrity of the matrix would
be preserved as a mechanical support for propulsive move-
ment (3, 5, 6, 11–15).
Based on the ability of the plasminogen activator-plasmin-
ogen axis to rapidly dissolve intravascular fibrin deposits, it
has been generally assumed that cell surface-associated plas-
min plays a key, if not necessary, role in driving the fibrin-
invasive phenotype in the extravascular compartment (5, 6,
11, 12). However, in plasminogen-null animals, fibrin-rich
tissues are infiltrated efficiently by normal as well as neoplas-
tic cell types despite significant defects in intravascular fi-
brinolysis (3, 9, 16–18). Consequently, increased attention
has focused on the identification of alternate proteolytic sys-
tems that would allow cells to infiltrate fibrin matrices via a
plasminogen-independent process. Recently, we identified
an unexpected role for matrix metalloproteinases (MMPs)
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in fibrin-invasive activity (3). The MMP gene family con-
sists of 25 proteinases, of which 18 are secreted and 7 are
membrane-associated either as transmembrane- or GPI-
anchored enzymes (19–21). In our earlier studies, a mem-
brane-anchored MMP, termed MT1-MMP, which is ex-
pressed in fibroblasts and endothelial cells, was able to
confer a fibrin-invasive phenotype to invasion-incompe-
tent, recipient cells after transfection (3). However, in the
absence of specific MT1-MMP inhibitors or gene-deleted
animals, the functional importance of this metalloproteinase
in a physiologically relevant cell population has remained
the subject of conjecture. This issue has been further com-
plicated by the fact that more recent studies have demon-
strated that an expanding number of secreted MMPs like-
wise express fibrin(ogen)olytic activity (3, 22–27). Given
the recent generation of MT1-MMP–deleted mice (28, 29),
we undertook studies to determine the ability of this pro-
teinase as well as other fibrin(ogen)olytic MMPs to regulate
fibrin invasion. We now demonstrate that whereas wild-
type fibroblasts utilize MMPs to penetrate cross-linked fi-
brin gels under physiologic conditions, MT1-MMP–null fi-
broblasts unexpectedly display only a transient defect in
fibrin-invasive activity. Further studies reveal that an addi-
tional subset of membrane-anchored MMPs, including
MT2-MMP and MT3-MMP, but not MT4-MMP, allow
cells to traverse fibrin matrices independently of MT1-
MMP. These findings identify a triad of MT-MMPs whose
expression, alone or in combination, is sufficient to confer
fibrin-invasive activity. We posit that normal or neoplastic
cells expressing any of these three MT-MMPs will display
potent fibrin-invasive activity that functions independently
of the plasminogen activator-plasminogen axis.
 
Materials and Methods
 
Cell Culture.
 
MDCK and CHO-K1 cell lines (both from
American Type Culture Collection) were maintained in DMEM
and RPMI 1640 (GIBCO BRL), respectively, supplemented
with 10% fetal bovine serum (Hyclone), 2 mM L-glutamine, and
antibiotics as described (30). Stably transfected MDCK cells were
maintained in medium containing 700 
 
 
 
g/ml G418 (Life Tech-
nologies). Mouse fibroblasts were isolated from dermal explants
of MT1-MMP null or wild-type littermates as described (31) and
used between the third and sixth passages. All cultures were
maintained at 37
 
 
 
C in 5% CO
 
2
 
/95% air.
 
Expression Vector Construction and Transfection.
 
Expression
vectors including FLAG-tagged MT1-MMP, MT2-MMP, and
MT3-MMP as well as stably transfected MDCK cells overex-
pressing MMPs 2, 3, 7, 9, 11, 13, MT1-, 2-, and 3-MMPs have
been described in detail previously (30). To generate FLAG-
tagged full-length MT4-MMP, primers encoding the FLAG
epitope (5
 
 
 
-GACTACAACGACGACGATGACAAG-3
 
 
 
) were
inserted after the COOH-terminal leucine of full-length MT4-
MMP (provided by M. Seiki, University of Tokyo, Tokyo, Ja-
pan) and the epitope-tagged construct cloned into the pSG5 vec-
tor. Soluble His-tagged MT1-, MT2-, and MT3-MMPs were
generated by inserting primers encoding the His epitope (5
 
 
 
-AT-
GATGATGATGATGATG-3
 
 
 
) after the COOH-terminal gly-
cine of soluble MT1-MMP (Met
 
1
 
-Gly
 
535
 
), the COOH-termi-
nal asparagine of soluble MT2-MMP (Met
 
1
 
-Asn
 
625
 
), and the
COOH-terminal alanine of soluble MT3-MMP (Met
 
1
 
-Ala
 
564
 
)
using a PCR-based method and cloned into pCR3.1-Uni. An
expression vector for 
 
 
 
1
 
 antitrypsin Portland (
 
 
 
1
 
PDX) was con-
structed from cDNA provided by G. Thomas (Oregon Health
Sciences Center, Portland, OR [32]). CHO-K1 cells were tran-
siently transfected with purified plasmid DNA using Fugene
(Roche) according to the manufacturer’s instructions. The activ-
ity of the soluble MT-MMPs was monitored with the quenched
fluorescent peptide (7-methoxycoumarin-4-yl)acetyl-prolyl-leu-
cyl-glycyl-leucyl-[3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl]-
alanyl-arginamide (Bachem) as described (33).
 
Reverse Transcription PCR Analysis.
 
RNA was isolated from
MT1-MMP wild-type or null fibroblasts using TRIzol reagent
(Life Technologies). Reverse transcription was performed as de-
scribed previously (3). cDNAs of MMPs were amplified by PCR
using specific oligonucleotide primers for MT1-MMP (sense 5
 
 
 
-
TGCGACGGGAACTTTGACACCG-3
 
 
 
; antisense 5
 
 
 
-TCCT-
CCTCAGTCCCCTCATC-3
 
 
 
; 607 bp product from 
 
1201
 
T to
 
1808
 
A), MT2-MMP (sense 5
 
 
 
-ACATGTCCACCATGCGC-
TCT-3
 
 
 
; antisense 5
 
 
 
-TACCATGATGTCAGCCTCC-3
 
 
 
; 391
bp product from 
 
222
 
A to 
 
613
 
A), MT3-MMP (sense 5
 
 
 
-CGGTG-
TACCAGACCAGACAA-3
 
 
 
; antisense 5
 
 
 
-ATTGGGATTTC-
CCAGTGTCC-3
 
 
 
; 402 bp product from 
 
357
 
C to 
 
756
 
T). The
identity of the isolated cDNAs was confirmed by sequence analy-
sis (3).
 
Invasion, Motility, and Fibrinolysis Assays.
 
Fibrin gels were cast
in the upper wells of 24-mm Transwell dishes (3 
 
 
 
m pore size;
Corning, Inc.) by combining 0.5 ml of plasminogen-free human
fibrinogen (6 mg/ml; Calbiochem) with 0.5 ml of human throm-
bin (4 U/ml; Sigma-Aldrich) in Hanks Balanced Salt Solution
(pH 7.4) alone or supplemented with 200 
 
 
 
g/ml aprotinin
(Sigma-Aldrich [3, 10]). Type I collagen gels were prepared as
described previously (30). Because the fibrinogen preparation
contains transglutaminase and fibronectin, the fibrin gel contains
 
 
 
-
 
 
 
 crosslinks, 
 
 
 
-polymers, and covalently-incorporated fi-
bronectin (3, 4). Where indicated, fibrinogen preparations were
depleted of fibronectin by gelatin-affinity chromatography (34).
The gels were incubated at 37
 
 
 
C for 2 h to allow complete gel-
ling. To vary fibrin fiber size, polymerization rates were varied by
incubating thrombin-fibrinogen mixtures at pH 6.9, 7.4, or 8.0
(35). After the fibrin gels were cast at the indicated pH, 1–5 
 
 
 
10
 
5
 
 MDCK cells, CHO-K1 cells, wild-type, or MT1-MMP null
fibroblasts in complete medium containing 10% fetal bovine se-
rum were cultured atop the fibrin matrix. After 24 h, recombi-
nant scatter factor/hepatocyte growth factor (SF/HGF) was
added to the lower chamber at 50 ng/ml for MDCK cells (30).
CHO-K1 cells were transiently transfected with the indicated
plasmids and SF/HGF (50 ng/ml) added to the bottom well 24 h
later. Wild-type or MT1-MMP null fibroblasts were similarly
treated, but invasion stimulated with platelet-derived growth fac-
tor (PDGF)-BB (herein referred to as PDGF, 15 ng/ml; Calbio-
chem). Fibroblast motility was monitored by culturing cells atop
fibrin gels whose surface was partially covered with glass cloning
chips (3). After confluent layers of fibroblasts were formed, the
chips were removed leaving denuded areas wherein the distance
migrated by the advancing front of cells (three cells or more) was
measured during a 24 h incubation. Where indicated, recombi-
nant tissue inhibitor of metalloproteases-1 (TIMP-1; 50 
 
 
 
g/ml),
tissue inhibitor of metalloproteases-2 (TIMP-2; 20 
 
 
 
g/ml), or
the synthetic MMP inhibitor, BB-94 (5 
 
 
 
M final concentration
in 0.1% DMSO; gift of British Biotechnology, Oxford, UK) was
included in the fibrin gel and added to the medium (3, 30). En-
dotoxin-free TIMP-1 and TIMP-2 (Fuji Chemicals) were active- 
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site titrated with gelatinase A before use (specific activity of
TIMP-2 was 2.5 times greater than that of TIMP-1). All media,
including SF/HGF or PDGF and inhibitors was exchanged every
2 d during the assay period (MDCK invasion was routinely ter-
minated at 5 d, CHO-K1 invasion at 5 d, and fibroblast invasion
at 6 d unless indicated otherwise). The number of invasive foci
and depth of invasion (mean depth of the three front-leading
cells/field) were determined from digitized images of 10 ran-
domly selected 40
 
 
 
 fields of hematoxylin and eosin (H and E)-
stained cross sections (3, 30). All results were confirmed with sta-
ble transfectants in three or more cloned cell lines.
Fibrinolytic activity was determined by culturing cells atop fi-
brin gels containing 
 
125
 
I-labeled fibrinogen (Amersham Pharma-
cia Biotech) in the presence of aprotinin (200 
 
 
 
g/ml) with or
without BB-94 as described above. Fibrin degradation products
in the cell-free media and in 5 M urea extracts of the fibrin gel
were pooled and quantitated by 
 
 
 
-scintillation counting (3).
Spontaneous release of 
 
125
 
I-fibrin from gels incubated in the ab-
sence of cells was subtracted from all values and the results pre-
sented as mean cpm 
 
 
 
 1 SD.
 
Western Blots.
 
The expression of MMP proteins in tran-
siently transfected CHO cells was assessed by Western blotting.
FLAG-tagged MT-MMP proteins were recovered from Triton-
X114 extracted cells as described previously (32). To detect solu-
ble, His-tagged MT1, MT2, and MT3-MMPs, CHO-K1 cells
were transferred to serum-free medium 24 h after transfection
and incubated for an additional 24 to 48 h. Cell-free supernatants
and detergent extracts (in the case of the full-length MT-MMPs)
were resolved on 10% polyacrylamide gels under reducing con-
ditions and the proteins transferred to nitrocellulose membranes
(32). FLAG-tagged proteins were detected with mouse mono-
clonal antibody M2 against a FLAG epitope (1:1,000; Sigma-
Aldrich), while soluble MT-MMPs were detected with mouse
monoclonal Penta-His antibody (1:2,000; QIAGEN). Blots
were probed with a horseradish peroxidase-conjugated anti–
mouse IgG secondary antibody and bands visualized using the
ECL system according to the manufacturer’s instructions (Pierce
Chemical Co.).
 
Histology and Electron Microscopy.
 
For histological sections, fi-
brin or type I collagen gels were fixed in 4% paraformaldehyde
in phosphate buffered saline (pH 7.4), dehydrated through a
graded ethanol series, and embedded in paraffin. Sections were
cut at 7 
 
 
 
m and stained with hematoxylin and eosin (3, 30). For
electron microscopy, fibrin gels were fixed in 2% glutaralde-
hyde/1.5% paraformaldehyde in 0.1 M sodium cacodylate
buffer, postfixed in 1% osmium tetroxide, and dehydrated
through graded ethanol. Samples were then embedded in epoxy
resin, 500 nm sections cut, and stained with uranyl acetate and
lead citrate. For scanning electron microscopy (SEM) analyses,
after dehydration in ethanol, samples were incubated in 50:50
ethanol:hexamethyldisilazane followed by a 20-min incubation
in 100% hexamethyldisilazane. Air dried specimens were
mounted, sputter coated with gold, and viewed on an Amray
1000-B scanning electron microscope.
 
Results
 
Fibrinolytic and Fibrin-Invasive Activity of MMPs in Stably
Transfected Cells.
 
Matrix remodeling events at sites of fi-
brin deposition in vivo are associated with the expression
of a complex mix of soluble MMPs, including MMP-1
(collagenase-1), MMP-13 (collagenase-3), MMP-2 (gelati-
 
nase A), MMP-9 (gelatinase B), MMP-3 (stromelysin-1),
MMP-11 (stromelysin-3), and MMP-7 (matrilysin) (1, 16,
18, 36). Each of these MMPs has been reported to degrade
fibrin(ogen) under serum-free and cell-free conditions (3,
22–24, 26, 27), but the ability of these proteinases to medi-
ate fibrin-degradative or invasive events by intact cells un-
der physiologically relevant conditions is unknown. Conse-
quently, invasion-incompetent cells engineered to stably
overexpress each of these fibrinolytic MMPs were cultured
atop 
 
125
 
I-labeled fibrin gels in the presence of 10% serum
and motility stimulated by exogenous HGF/SF. Fibrinoly-
sis as well as invasion were then monitored during a 5-d in-
cubation period. As shown in Fig. 1 A, each of the MMP
transfectants as well as the control-transfected cells ex-
pressed fibrinolytic activity that could be suppressed by the
peptidomimetic MMP inhibitor, BB-94 (5 
 
 
 
M). How-
ever, neither the control-transfected cells nor any of the
clones that overexpressed the secreted MMPs penetrated
the underlying fibrin gels (Fig. 1, A and B). By contrast,
stable clones overexpressing the membrane-anchored pro-
teinase, MT1-MMP, not only expressed fibrinolytic activ-
ity, but as described previously (3), displayed fibrin-invasive
activity as well (Fig. 1, A and B). As expected, MT1-
MMP–dependent fibrinolytic and invasive activity were
both inhibited in the presence of BB-94 (77 
 
 
 
 6% and
100 
 
 
 
 0% for fibrinolysis and invasion, respectively;
mean 
 
 
 
 1 SD, 
 
n
 
 
 
  
 
4).
 
Regulation of Fibroblast-Fibrin Interactions by MT1-
MMP.
 
Despite the fact that MT1-MMP (a) uniquely
conferred fibrin-invasive activity to transfected cells relative
to all of the secreted MMPs tested and (b) is known to be
expressed in fibroblasts at sites of fibrin deposition in vivo
(16, 18, 36), the role of this, or other, MMPs in regulating
fibroblast-fibrin interactions has not been defined previ-
ously. To determine whether fibroblast-derived MMPs
regulate fibrin-invasive activity, wild-type mouse cells were
cultured atop fibrin gels and motility stimulated with
PDGF in the absence or presence of class-specific antipro-
teinases. After 2 d in culture, PDGF-stimulated fibroblasts
had penetrated the underlying gel with peak invasion oc-
curring by day 6 (Fig. 2, A and C). As assessed by transmis-
sion electron microscopy (TEM), 4 to 6-d-old cultures re-
vealed zones of cleared fibrin juxtaposed to the invading
cells (Fig. 2 B) which correlated with the detection of de-
graded fibrin in the fluids expressed from the gels (at day 4,
wild-type fibroblasts released 6,540 cpm 
 
125
 
I-fibrin and
17,380 cpm at day 6; 
 
n
 
 
 
  
 
2). While fibroblast invasion was
unaffected by inhibitors directed against serine proteinases
(aprotinin, soybean trypsin inhibitor, or plasminogen-
depletion), cysteine proteinases (E-64), or aspartyl protein-
ases (pepstatin A), PDGF-stimulated cells were unable to
penetrate the fibrin gels in the presence of BB-94 during
the 6 d culture period (Fig. 2 A; 100 
 
 
 
 0% inhibition;
mean 
 
 
 
 1 SD, 
 
n
 
 
 
  
 
3).
Wound-associated fibroblasts have been shown to ex-
press MMP-2, MMP-11, and MT1-MMP in vivo (16, 18,
36), but only the latter proteinase scored positive in our 
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screen of pro-invasive MMPs. Consequently, MT1-MMP-
null fibroblasts were isolated from the gene-deleted animals
and assessed for their ability to invade the fibrin gels under
conditions identical to those used for the wild-type cells.
After the first 2 d in culture, PDGF-stimulated MT1-MMP
null cells displayed a striking deficiency in invasive potential
(Fig. 2, A and C) with the number of invasive foci reaching
levels only 27 
 
 
 
 0.3% of control value (mean 
 
 
 
 1 SD; 
 
n
 
 
 
 
 
3). Surprisingly, however, the defect in invasive activity
was only transient as the null cells began to invade the fibrin
matrix after a 3-d lag where invasion reached 60–70% of
control values by day 6 (Fig. 2 C). Similar to the behavior
of the wild-type cells, zones of fibrin clearing were found in
association with the invading null fibroblasts which also
proteolyzed fibrin comparably to control cells (i.e., 16,260
cpm 
 
125
 
I-fibrin released by null fibroblasts versus 17,380
cpm for wild-type cells by day 6; 
 
n
 
 
 
 
 
 2; Fig. 2 B).
To determine whether the delayed fibrin-invasive activ-
ity of MT1-MMP–deficient fibroblasts could be linked to
the expression of other MMP family members, the null fi-
broblasts were stimulated with PDGF atop fibrin gel in the
presence of BB-94. As shown in Fig. 2 A, BB-94 com-
pletely prevented fibrin invasion by the null cells (100 
 
 
 
0% inhibition; mean 
 
 
 
 1 SD, 
 
n
 
 
 
  
 
3). Significantly, while
MMP activity has been linked to the migratory response of
other cell types across matrix-coated surfaces (e.g., refer-
ences 37–41), the two-dimensional movement of PDGF-
stimulated wild-type or null cells cultured atop fibrin gels
was not inhibited by BB-94 (Fig. 2 D) and leading front
determinations demonstrated that wild-type cells incubated
in the absence or presence of BB-94 migrated 0.69 
 
 
 
 0.04
mm and 0.67 
 
 
 
 0.03 mm, respectively, while null cells mi-
grated 0.65 
 
 
 
 0.07 mm and 0.66 
 
 
 
 0.04 mm in the ab-
sence or presence of BB-94 (mean 
 
 
 
 1 SD, 
 
n
 
 
 
  
 
3).
 
Characterization of MT1-MMP-Independent Fibrin-Invasive
Activity.
 
As BB-94 inhibits secreted as well as membrane-
anchored MMPs with near equivalent efficiency (3, 30),
the MT1-MMP-independent process used by the null fi-
broblasts could be mediated by either group of MMPs.
Consequently, we took advantage of the ability of the en-
dogenous MMP inhibitor, TIMP-1, to preferentially in-
hibit secreted MMPs in contrast to the ability of the related
inhibitor, TIMP-2, to target secreted as well as membrane-
anchored MMPs (3, 19, 30). Hence, wild-type and MT1-
MMP null fibroblasts were cultured atop fibrin gels and
stimulated with PDGF in the absence or presence of
equimolar concentrations of active TIMP-1 or TIMP-2. As
shown in Fig. 3, while the invasive activity of wild-type or
null fibroblasts was unaffected by TIMP-1, invasion was
completely inhibited by TIMP-2 (Fig. 3, A and B). The in-
hibitory effects of TIMP-2 were confined to three-dimen-
sional invasion as neither TIMP-2 nor TIMP-1 affected the
two-dimensional migratory response of fibroblasts stimu-
lated atop fibrin gels (data not shown).
Figure 1. Fibrin-degradative and
invasive activities of MDCK stable
transfectants overexpressing secreted
MMPs or MT1-MMP. (A) Control
vector-transfected or MMP-express-
ing transfectants were cultured atop
125I-labeled fibrin gels in complete
medium with 10% FBS and SF/HGF
(50 ng/ml) for 5 d in the absence
(light gray bars) or presence of 5  M
BB-94 (dark gray bars). Solubilized
125I-fibrin was monitored as de-
scribed in the Materials and Methods
and expressed as the mean cpm   1
SD (n    4). (B) H and E–stained
transverse sections of control vector-
transfected and MMP-overexpress-
ing clones cultured atop fibrin gels as
described above in the presence of
SF/HGF for 5 d. Only MT1-MMP
transfectants expressed invasive be-
havior (arrows) which was com-
pletely blocked in the presence of
BB-94. The double-headed arrow in
the first panel demarcates the under-
lying fibrin gel which is largely
transparent in H and E–stained sec-
tions. Bar   100  m. 
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Among the other membrane-anchored MMPs that are
preferentially sensitive to TIMP-2, MT2-MMP, and MT3-
MMP appear to be among the most widely expressed in
vitro or in vivo (30, 42–47). To determine whether fibro-
blasts expressed either of these MT-MMPs, wild-type or
MT1-MMP null cells were cultured atop fibrin gels, stimu-
lated with PDGF for 3 d, and isolated RNA amplified by
reverse transcription (RT)-PCR using the corresponding
MT-MMP-specific primers (Fig. 3 C). Interestingly, while
MT2-MMP could not be detected in either fibroblast pop-
ulation, both the wild-type and MT1-MMP-null fibro-
blasts expressed MT3-MMP. Consistent with these data,
MT1-MMP-null fibroblasts retained a diminished ability to
activate proMMP-2 via a process inhibitable by TIMP-2 or
BB-94, but not TIMP-1 (data not shown).
To determine directly whether MT3-MMP can confer a
fibrin-invasive activity comparable to that observed for
MT1-MMP, an invasion-incompetent cell population (i.e.,
Figure 2. Invasive and migratory behav-
ior of MT1-MMP /  and MT1-MMP / 
fibroblasts. (A) H and E–stained transverse
sections of wild-type littermate and MT1-
MMP-null fibroblasts cultured atop fibrin
gels in the presence of 10% FBS with inva-
sion stimulated by the addition of PDGF to
the basilar compartment. Invasion of MT1-
MMP /  fibroblasts commenced at day 2
(top left panel) and peaked at day 6 (middle
panel). Invasion of MT1-MMP-null fibro-
blasts was not observed in most sections at
day 2 (bottom left panel), but accelerated to
near-normal values by day 6. In the pres-
ence of BB-94, invasion of wild-type and
null fibroblasts was inhibited completely.
Bar   100  m. (B) TEM analysis of fibrin-
invasive MT1-MMP /  and MT1-MMP / 
fibroblasts. Invasive wild-type and null fibro-
blasts were both pocketed by zones of
cleared fibrin (arrows). Bars   5  m for
MT1-MMP /  and 2  m for MT1-
MMP /  samples. (C) MT1-MMP /  and
MT1-MMP /  fibroblasts were cultured
atop fibrin gels in the absence or presence of
PDGF and the number of invasive foci
monitored at the indicated times. Results
are expressed as the mean number of invad-
ing cells/field   1 SD (n   3). (D) Two-
dimensional migration of PDGF-stimulated
MT1-MMP /  and MT1-MMP /  fibro-
blasts that were cultured atop fibrin gels and denuded by wounding in the absence or presence of BB-94 for 24 h. Arrow marks the edge of the confluent
fibroblast layer after wounding as viewed by phase contrast microscopy. Bar   100  m. 
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CHO-K1 cells) was transiently transfected with either of
the epitope-tagged MT-MMPs and fibrin invasion moni-
tored in the presence of 10% serum as described. While
control transfected CHO-K1 cells showed little, if any,
BB-94-sensitive invasive activity, MT1-MMP transfected
cells readily penetrated the gels (Fig. 4, A and D). Signifi-
cantly, MT3-MMP-transient as well as stable transfectants
displayed similar activity despite the fact that the levels of
MT3-MMP protein expressed (as assessed by Western blot
analysis with anti-M2 FLAG monoclonal antibody) were
consistently lower than those detected for MT1-MMP
(Fig. 4, A–C). Finally, in a fashion similar to that observed
in the wild-type or MT1-MMP null fibroblasts, MT3-
MMP–dependent invasion was completely resistant to
TIMP-1, but equally sensitive to BB-94 or TIMP-2 (Fig. 4
D). Cells cotransfected with MT1-MMP and MT3-MMP
did not display synergistic invasive behavior (data not
shown). Hence, the fibrin-invasive properties of MT1-
MMP can be extended to include the membrane-anchored
metalloproteinase, MT3-MMP.
 
Fibrin-Invasive Activity Can Be Extended to MT2-MMP,
but not MT4-MMP.
 
While fibroblasts can preferentially
rely on either MT1-MMP or MT3-MMP to negotiate fi-
brin barriers, a variety of normal as well as neoplastic cell
populations display different repertoires of membrane-
 
anchored metalloproteinases which include MT2-MMP and/
or MT4-MMP (25, 42–47). To determine whether fibrin-
invasive activity is restricted to MT1- and MT3-MMP,
cells were transfected with either MT2- or MT4-MMP
and invasive activity monitored. Significantly, despite the
fact that the isolated catalytic domain of MT2-MMP has
been reported to express little, if any, fibrinolytic activity
(23), transiently transfected CHO-K1 cells (as well as stably
transfected cells) expressed an invasive phenotype compara-
ble to that observed for MT1-MMP and MT3-MMP (Fig.
5, A–C). Likewise, the invasion by MT2-MMP transfec-
tants could be blocked completely by TIMP-2 or BB-94,
but not TIMP-1 (Fig. 5, B, C, and E).
The ability of MT1-, 2-, and 3-MMP to promote fibrin
invasion contrasts with the inability of each of the secreted
MMPs to confer similar activities (see Fig. 1). Among the
MMPs tested, only MMP-11 (stromelysin-3) and
MT-MMP prodomains include a proprotein recognition
motif that allows these proteinases to undergo efficient pro-
cessing to their enzymically active forms (19, 32, 48). To
determine whether MT-MMPs confer invasive activity
when secreted as fully active, but no longer membrane
tethered, enzymes, each of the proteinases were alterna-
tively expressed as epitope-tagged, transmembrane-deleted
mutants. As shown in Fig. 5 A (right panel), the soluble
Figure 3. Effect of TIMP-1 and TIMP-2 on the fibrin-invasive activity
of MT1-MMP /  and MT1-MMP /  fibroblasts. (A) H and E–stained
transverse sections of PDGF-stimulated MT1-MMP /  and null fibro-
blasts cultured atop fibrin gels in either 10% FBS alone or supplemented
with TIMP-1 (50  g/ml) or TIMP-2 (20  g/ml) for 6 d. Bar   100  m.
(B) The number of invasive foci and depth of invasion was quantified for
MT1-MMP /  and MT1-MMP /  fibroblasts cultured in the absence or
presence of TIMP-1 and TIMP-2. Results are expressed as the mean   1
SD of three experiments. (C) RT-PCR analysis of MT1-MMP and
MT3-MMP expression in wild-type and null cells cultured atop fibrin
gels and stimulated with PDGF for 72 h. The 402 bp MT-3 transcript was
confirmed by sequence analysis. MT2-MMP-specific transcripts were not
detected under these conditions. 
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MT-MMPs were all expressed as a higher M
 
r
 
 proform and
a lower M
 
r
 
 active enzyme whose activity was confirmed by
fluorometric assay (see Materials and Methods). The iden-
tity of the slower migrating bands as the MT-MMP pro-
forms was confirmed by cotransfecting cells with the pro-
protein convertase inhibitor, 
 
 
 
1
 
PDX
 
32
 
, which blocked
soluble MT-MMP processing (Fig. 5 A). However, despite
the fact that transfected cells secreted active MT-MMPs ef-
ficiently, no fibrin-invasive activity was detected (Fig. 5 D).
Given the apparent requirement that fibrinolytic MMPs
must be membrane-anchored to drive invasion, the activity
of MT4-MMP, a GPI-anchored metalloproteinase, was as-
sessed. However, despite the fact that soluble MT4-MMP
can degrade fibrin(ogen) (25), the GPI-anchored proteinase
did not promote fibrin-invasive activity under any of the
conditions tested (Fig. 5, A, C, and E). Although MT4-
MMP, unlike MT1-, 2-, or 3-MMP cannot process gelati-
nase A to its active form (25), the pro-invasive phenotypes
displayed by MT1-, MT2-, or MT3-MMP–transfected
cells was not affected under either gelatinase A–depleted
conditions or when cells were cotransfected with gelatinase
A (data not shown).
 
MT-MMP–dependent Invasion.
 
In vivo
 
,
 
 networks of
polymerized fibrin can vary dramatically in terms of fiber
size, density, rigidity, and sensitivity to proteolytic degrada-
tion (35, 49–51). To determine the ability of MT-MMP–
transfected cells to degrade and invade fibrin gel networks
exhibiting different physical properties, fibrinogen was po-
lymerized at pH 6.9–8.0 (Fig. 6). At acidic pH, the poly-
merization process is slowed, favoring the formation of
thicker, more rigid fibrillar networks while at alkaline pH,
polymerization is accelerated generating thinner, more
malleable structures (35, 49–51). Though thinner fibrils are
more resistant to proteolytic attack by the plasminogen ac-
tivator-plasminogen system (35, 51), stably transfected cells
overexpressing MT1-MMP, MT2-MMP, or MT3-MMP
rapidly spread on each of the matrices and degraded the
underlying gel at comparable rates (Fig. 6, A and B). Like-
wise, no differences were detected in the ability of the
transfectants to penetrate or invade the gels (Fig. 6, C and
D). Fibrin fiber size and gel characteristics are also affected
by the covalent incorporation of fibronectin into the fibril-
lar network by transglutaminase (35, 50). As MT1, 2, and
3-MMPs are able to degrade fibronectin (33, 52–54), we
considered the possibility that the degradation of gel-incor-
porated fibronectin may have contributed to the invasive
phenotype. However, stable transfectants cultured atop
transglutaminase cross-linked fibrin gels formed from fi-
bronectin-depleted fibrinogen exhibited similar degradative
and invasive behavior (data not shown). Finally, while the
ability of MT1-, 2-, and 3-MMP transfectants to degrade
and/or invade fibrin barriers in comparable fashion suggests
that each of these metalloproteinases share overlapping sub-
strate profiles, their interchangeable phenotypic behavior
was limited to the fibrin substratum (Fig. 7). In paired ex-
periments, when MT-MMP transfectants were cultured
atop type I collagen gels, only MT1-MMP accelerated in-
vasion while the MT2-MMP and MT3-MMP transfectants
displayed a reduced invasive activity relative to the control
transfected cells (Fig. 7). Hence, whereas a different reper-
toire of MT-MMP activities must be used for traversing
the type I collagen-rich interstitium (30), each of the three
Figure 4. MT3-MMP-dependent fibrin-invasive activity. (A) TEM
sections of control vector-, MT1-MMP-, and MT3-MMP–transfected
CHO-K1 cells cultured atop fibrin gels in 10% FBS and stimulated with
SF/HGF in the absence or presence of BB-94 for 5 d. Bar   10  m. (B)
Western blot analysis of CHO-K1 cells transfected with a control vector,
FLAG-tagged MT1-MMP, or FLAG-tagged MT3-MMP. (C) H and
E–stained transverse sections of MDCK stable transfectants overexpress-
ing MT3-MMP cultured atop fibrin gels and stimulated with SF/HGF for
5 d in the absence or presence of BB-94. Bar   100  m. (D) CHO-K1
cells transiently transfected with control-, MT1-MMP-, or MT3-MMP-
expression vectors were cultured atop fibrin gels for 5 d and the number
of invasive foci/field and invasion depth were quantified in the absence or
presence of TIMP-1, TIMP-2, or BB-94. Results are expressed as the
mean   1 SD of three experiments. 
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MT-MMPs arm cells with the ability to negotiate fibrin
barriers with equal efficiency.
 
Discussion
 
The proteolytic processes used by normal or neoplastic
cells to penetrate the fibrin deposits that surround wounds,
inflammatory sites, or tumor foci have remained largely
undefined (2–13). Given the efficiency with which plasmin
degrades fibrin relative to other proteinases, it has been
generally assumed that the plasminogen activator-plasmin-
ogen axis would serve as the sole determinant of invasive
activity (5, 6, 11, 12). While plasmin can participate in fi-
brin-invasive events in vitro or in vivo (5, 6, 11, 12, 55),
studies in plasminogen-deficient mice have demonstrated
that alternate proteolytic systems exist that allow cells to
readily infiltrate fibrin-rich tissues in pathophysiologic set-
tings (e.g., references 9, 16–18, and 56). Coincident with
Figure 5. Fibrin-invasive potential of MT2-MMP,
MT4-MMP, and transmembrane-deleted mutants. (A)
Western blot analysis of CHO-K1 cells transiently trans-
fected with a control vector, FLAG-tagged full-length
MT2-MMP, or FLAG-tagged full-length MT4-MMP
(left panel). Alternatively, CHO-K1 cells were transiently
transfected with a control vector, transmembrane-deleted
MT1-MMP (MT1-MMPs), MT2-MMPs, or MT3-
MMPs containing a His-tag epitope at their carboxy ter-
mini in the absence or presence of an  1PDX expression
vector. In the presence of  1PDX, the proform of each of
the soluble MT-MMPs was the predominant species de-
tected. (B) TEM sections of CHO-K1 cells transiently
transfected with MT2-MMP cultured atop a fibrin gel in
10% FBS with SF/HGF in the absence or presence of
BB-94. Bar   10  m. (C) H and E–stained sections of
MDCK cells stably transfected with MT2-MMP or
CHO-K1 cells transiently transfected with MT4-MMP
and cultured atop fibrin gels as described above, in the ab-
sence or presence of BB-94. Bar   100  m. (D) CHO-K1
cells transiently transfected with MT1-MMPs, MT2-MMPs,
or MT3-MMPs did not invade the underlying fibrin gel af-
ter a 5 d incubation period. Bar   50  m. (E) Invasive
foci/field and invasion depth for SF/HGF-stimulated
CHO-K1 cells transiently transfected with a control vec-
tor, MT2-MMP, or MT4-MMP and cultured atop fibrin
gels in the absence or presence of TIMP-1, TIMP-2, or
BB-94 was determined as described above. Results are
expressed as the mean   1 SD of three experiments. 
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these findings, increased awareness has focused on the fact
that the substrate repertoire of MMPs can be extended
from structural components of the “mature” extracellular
matrix (i.e., collagens, elastins, glycoproteins, and pro-
teoglycans) to fibrin(ogen), the major component of the
provisional matrix (3, 22, 23, 25, 26). Nonetheless, fi-
brin(ogen)olytic activity need not correlate with the ability
of a given proteinase to confer an invasive phenotype as
pericellular degradation must proceed in an orchestrated
fashion that allows the cell to tunnel through the substra-
tum while retaining sufficient matrix to act as a structural
support for movement (3, 10, 14, 15, 57).
Recently, we reported that invasion-incompetent cells
can be induced to penetrate fibrin matrices after transfec-
 
tion with MT1-MMP cDNA (3). However, the role that
the proteinase plays in regulating the fibrin-invasive activ-
ity of wild-type cells has remained unclear. Further, the
relative importance of MT1-MMP in promoting fibrin
invasion has been questioned as a large series of soluble
MMPs have been subsequently reported to degrade
fibrin(ogen) with similar, if not greater, efficiency (3,
22–27). To order the fibrin(ogen)olytic MMPs in
terms of their pro-invasive potential, invasion-incom-
petent cells were transiently or stably transfected with
fibrin(ogen)olytic metalloproteinases. Significantly, whereas
MT1-MMP overexpressing cells readily invaded cross-
linked fibrin gels, neither collagenases (MMP-1 or
MMP-13), gelatinases (MMP-2 or MMP-9), stromelysins
Figure 6. Effect of fibrin diameter on fibrinolytic and
invasive activity of MT1-MMP-, MT2-MMP-, or MT3-
MMP–expressing stable transfectants. (A) Fibrin gels pre-
pared at pH 6.9, 7.4, or 8.0 form fibrils with mean diame-
ters of 211   60 nm, 149   51 nm, and 81   30 nm
(mean   1 SD) as assessed by SEM (top three panels;
Bar   1  m), and supported comparable cell adhesion
(bottom three panels; Bar   10  m). B, C, and D depict
the fibrinolytic activity, number of invasive foci and depth
of invasion for control-, MT1-MMP-, MT2-MMP-, and
MT3-MMP-stable MDCK transfectants stimulated with
SF/HGF and cultured atop fibrin gels prepared at pH 6.9
(dark gray bars), 7.4 (white bars), or 8.9 (light gray bars)
for 10 d. Results are expressed as the mean   1 SD of
three experiments.304 MMPs Regulate Fibrin-invasive Activity
(MMP-3 or MMP-11), nor matrilysin conferred invasive
activity.
Given that fibroblasts migrating into fibrin-rich tissues in
vivo express MT1-MMP (16–18, 36), the ability of fibro-
blasts isolated from wild-type or MT1-MMP–deleted mice
to penetrate fibrin gels was examined. While the mecha-
nisms used by wild-type fibroblasts has remained contro-
versial (e.g., see references 4, 5, and 12), PDGF-stimulated
fibroblasts invaded fibrin gels via an MMP-dependent pro-
cess that proved sensitive to BB-94 or TIMP-2, but not
TIMP-1. As BB-94 and TIMP-2 effectively inhibit all
MMP family members while TIMP-1–dependent inhibi-
tion is predominately restricted to secreted MMPs (3, 19,
25, 30), this profile supported a potential role for MT1-
MMP in fibrin invasion. Interestingly, secreted as well as
membrane-anchored MMPs have recently been implicated
in migratory responses of cells cultured atop various two-
dimensional substrata including type I collagen and lami-
nin-5 (37–41). The promigratory response has been alter-
natively linked with degradation of the underlying sub-
stratum, integrin processing, or proteolysis of surface-
associated transglutaminase (37–41, 58). However, in our
system, the inhibitory effects of BB-94 and TIMP-2 were
confined solely to effects on invasive behavior. Caution
should, however, be exercised in necessarily ascribing all
effects of these inhibitors to their ability to target MMPs.
For example, BB-94 and other peptidomimetic inhibitors
can affect cell responses by inhibiting metalloproteinases in
the adamalysin family responsible for the proteolytic shed-
ding of membrane-anchored ligands that can trigger
growth factor receptors (59–61). In contrast, TIMP-2 has
been reported to suppress mitogenesis independently of its
antiproteolytic activity (62). Nonetheless, despite these po-
tential caveats, neither fibroblast adhesion, proliferation,
nor migration were affected by BB-94 or TIMP-2 under
our experimental conditions. Though we had previously
reported that MMP inhibitors did not completely block fi-
broblast/myofibroblast migration from fibrin-embedded
tissue explants (3), subsequent studies have demonstrated
that cell egress in the presence of BB-94 or TIMP-2 is sig-
nificantly impaired and confined to a narrow zone sur-
rounding the tissue (unpublished observation).
Given that fibroblasts use an MMP-dependent process
to invade fibrin gels and express MT1-MMP in vivo (18,
36), we predicted that MT1-MMP–null fibroblasts would
fail to penetrate fibrin matrices. Indeed, during the first
2 d of the culture period, the MT1-MMP–deleted cells
expressed limited invasive behavior despite normal adhe-
sive and migratory responses atop fibrin gels. Surprisingly,
however, the activity of null cells rebounded and reached
levels comparable to those observed in the wild-type cells.
While the compensatory activity of the knockout cells to
express an invasive phenotype might have reflected the
use of an alternate class of proteinases, the residual activity
remained sensitive to BB-94 and TIMP-2, and hence, was
consistent with the participation of an alternate MT-
MMP. As predicted, MT1-MMP /  as well as MT1-
MMP-null fibroblasts expressed MT3-MMP in a fashion
similar to that reported for wild-type smooth muscle cells
stimulated with PDGF (47). Though neither MT3-MMP
specific inhibitors nor gene-deleted animals have been de-
scribed, we confirmed the ability of MT3-MMP to di-
rectly confer fibrin-invasive activity. We are currently
unable to compare MT1-MMP and MT3-MMP expres-
sion at the protein level in wild-type or null fibroblasts, as
mouse-specific antibodies are unavailable. However, using
epitope-tagged constructs, both MT-MMPs displayed
comparable activity when expressed at similar levels in
transiently transfected cells. Taken together, these data
support our contention that either MT1-MMP or MT3-
MMP can drive the fibrin-invasive phenotype in PDGF-
stimulated fibroblasts. Consistent with this interpretation,
MT1-MMP null cells were unable to traverse a type I col-
lagen matrix as MT3-MMP expresses minimal activity to-
ward this substrate (30; unpublished observation). While
other TIMP-2–sensitive MMPs might further modify fi-
Figure 7. Differential regulation of type I collagen- and fibrin-invasive
activity by MT-MMPs. H and E–stained cross-sections of the invasion
pattern displayed by MDCK cell clones stably transfected with control-,
MT1-MMP-, MT2-MMP-, or MT3-MMP-expression vectors and cul-
tured atop type I collagen (left series of panels) or fibrin (right series of
panels) in 10% FBS and stimulated with SF/HGF for 10 d. While control
MDCK invaded type I collagen, no invasive activity occurred atop fibrin
gels. Clones overexpressing MT1-MMP and cultured atop collagen gels
underwent a disrupted tubulogenesis program and expressed heightened
invasive activity. In the case of MT2-MMP– or MT3-MMP–overex-
pressing clones, collagen invasive activity was inhibited. These patterns of
invasion contrasted with the comparable fibrin-invasive activity of the
MT1-, MT2-, and MT3-MMP–overexpressing clones.305 Hotary et al.
brin-invasive activity in fibroblasts, neither MT5-MMP,
MT6-MMP, nor MMP-19 (a secreted MMP recently
shown to be preferentially sensitive to inhibition by
TIMP-2 [63]) were able to promote fibrin-invasive activ-
ity under our assay conditions (unpublished observation).
Fibroblasts can alternatively use MT1-MMP or MT3-
MMP to invade fibrin-rich deposits, but other cell popu-
lations (e.g., synoviocytes, leukocytes, trophoblasts, and
tumor cells) express distinct repertoires of membrane-
anchored metalloproteinases which include MT2-MMP
and MT4-MMP (19, 25, 42–47). Whereas the isolated cat-
alytic domain of MT2-MMP has been reported to be de-
void of fibrinolytic activity (23), a similar construct of
MT4-MMP was recently shown to degrade fibrinogen as
well as fibrin (25). In contrast to these reports, full-length
MT2-MMP, but not MT4-MMP, efficiently conferred fi-
brin-invasive potential. These findings highlight the im-
portance of using the intact enzymes rather than isolated
domains for functional characterization and are consistent
with reports documenting marked differences in activity
between catalytic domains, transmembrane-deleted con-
structs and the intact MMPs (33, 53, 64). Likewise, our
studies with MT4-MMP-transfected cells indicate that the
fibrin(ogen)olytic activity of an isolated enzyme may not
predict its ability to mediate invasive activity. Unlike
MT1, 2, or 3-MMP, MT4-MMP is GPI-anchored, its cat-
alytic domain does not include a characteristic insert (i.e.,
the so-called IS-2 domain), and the proteinase cannot acti-
vate progelatinase A (25, 65). However, these properties
do not likely underlie its inability to confer invasive activ-
ity as MT1-MMP retains fibrin-invasive activity when
GPI-anchored or its IS-2 domain is deleted (unpublished
observation). Further, gelatinase A does not express signif-
icant fibrinolytic activity nor does its exclusion affect fi-
brin-invasive activity (3, 23). Instead, the inability of
MT4-MMP to drive invasive activity may reside in the
fact that the proteinase cannot, in contrast to MT1-MMP,
efficiently degrade the high molecular weight  -polymers
of fibrin (3, 25). We speculate that the specific cleavage
sites chosen in the fibrin scaffolding may be important in
allowing the cell to penetrate the matrix while maintaining
the structural stability of the supporting network.
As MT1-MMP, MT2-MMP, or MT3-MMP are widely
distributed among normal and neoplastic cells (e.g., refer-
ences 19, 25, and 42–47), these metalloproteinases likely
constitute the plasminogen-independent arm of the fibrin-
invasive phenotype observed in vivo. However, unlike the
plasminogen activator-plasminogen axis wherein fibrino-
lytic activity is affected by fibrin structure or composition
(49–51), MT-MMP–dependent proteolysis and invasion
proceeded in an autonomous fashion. The lack of a plas-
minogen-dependent component in this invasion program is
also consistent with the proMT-MMP activation process.
While plasminogen mediates the activation of a number of
secreted MMPs (19), each of the MT-MMPs contains a ba-
sic motif (i.e., RXK/RR) at the COOH terminus of their
respective prodomains that serves as a recognition sequence
for one or more members of the proprotein convertase
family of serine proteinases (19, 32, 48). The convertases
activate the MT-MMP zymogens either intracellularly in
the trans-Golgi network or at the cell surface, thus allowing
the cell to directly control its proteolytic potential in a
trans-dependent fashion (19, 32, 48). Interestingly, though
the transmembrane-deleted MT-MMP mutants are also
processed efficiently by the proprotein convertases, only
the membrane-anchored forms of the proteinases expressed
functional activity in our invasion assay system. Given that
soluble MT1-MMP expresses fibrinolytic activity (3, 23,
26), these results lend credence to the notion that protein-
ases must be tethered to the cell surface to efficiently match
degradative activity with motility (14, 15, 30). MT-MMPs
may further require localization to specific regions of the
membrane actively involved in the invasive process (66,
67), but cytosolic domain-deleted forms of MT1-MMP re-
main functional (3, 30). Either surface localization signals
are no longer required when the proteinase is overex-
pressed or targeting information is encoded within the ex-
tracellular domain itself.
Our findings have focused on the fibrin-invasive activity
of MT-MMPs, but increasing evidence suggests that multi-
ple metalloproteinases may participate in the bulk resorp-
tion of fibrin deposits and affect coagulation by targeting fi-
brinogen as well as Factor XII (22–27). Significantly, fibrin
deposits were increased at wound sites in normal or plas-
minogen-deleted mice that were treated with a broad-spec-
trum MMP inhibitor (18). Coincident with these effects,
the delayed wound healing response of plasminogen-null
mice was further affected by the metalloproteinase inhibi-
tor, but this latter result should be interpreted cautiously as
effects on adamalysin-dependent shedding of surface-asso-
ciated growth factors (e.g., HB-EGF) must be considered
(68). This caveat aside, fibrin-degradation products consis-
tent with MMP-dependent proteolysis have been detected
in rheumatoid synovial fluid and MMP-9 has recently been
implicated in fibrinolytic events in an in vivo nephritis
model (22, 23, 27). In the latter studies, renal damage was
exacerbated in MMP-9 null mice and linked to increased
fibrin deposition (27). Further, while MMP-9 has been re-
ported to degrade fibrin rather inefficiently relative to other
secreted MMPs (e.g., MMP-3 or MMP-7; references 22
and 23), Lelongt et al. demonstrated that the proteinase
could efficiently degrade fibrin under their in vitro condi-
tions (27). In vivo, however, the situation is more complex
as ECM components such as type I collagen are deposited
into fibrin networks by fibroblasts (1). As these ECM-fibrin
composites display a heightened resistance to plasmin-depen-
dent fibrinolysis (69), secreted MMPs may play an impor-
tant role in fibrin clearance by either attacking fibrin(ogen)
directly or by collaborating with plasmin to dissolve the
stabilized fibrin deposits. Given evidence that MT-MMPs
maybe shed from the cell surface or expressed directly as
soluble enzymes (44, 70), this class of enzymes may either
promote invasion or function as bulk fibrinolysins depen-
dent on their presentation at the cell surface.
In summary, we have identified a subset of MT-MMPs as
the lead candidates responsible for allowing mammalian306 MMPs Regulate Fibrin-invasive Activity
cells to traverse fibrin-rich tissues in a plasminogen-inde-
pendent fashion. We note, however, that the comparable
activities of MT1-MMP, MT2-MMP, and MT3-MMP
with regard to fibrin-invasive activity do not similarly ex-
tend to other matrix barriers such as type I collagen. None-
theless, despite only  50% homology between MT1-MMP
and MT2-MMP or MT3-MMP at the amino acid level
(19), each of the membrane-anchored metalloproteinases
allows expressing cells to display comparable fibrin-invasive
and fibrinolytic activity. The ability of MT2-MMP and
MT3-MMP, but not other fibrinolytic MMPs, to confer fi-
brin-invasive activity in the absence or presence of MT1-
MMP, identifies a new pro-invasive system for traversing
the provisional matrix under pathophysiologic conditions.
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